8-K filing — HCW Biologics Inc. (HCWB)
Filed: 2026-09-10 AccNo: 0001493152-26-042009 Size: 210 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
HCW Biologics Signs Agreement With Akron Biotech To Commercialize HCW11-006 To Use As Reagent For New Method Of Human CAR-T Cells Production To Treat Cancer
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.
HCW Biologics Says It Received USPTO Notice Of Allowance For Claims Covering Use Of HCW9302 To Treat Alopecia Areata; Says Phase 1 Monotherapy Study On Track For Q4 2026 Completion